GOT2 and familial pancreatic carcinoma: Previous findings demonstrate that upon the knockout of GOT2 using CRISPR/Cas9 technology, pancreatic cancer cells deficient in GOT2 exhibited markedly restricted growth in immunocompetent syngeneic mouse models.